High Efficacy and Extensive clinical evidence
The loose combination of AS and MQ was demonstrated safe and efficacious in at least 745 trials involving over 11,000 patients in 20 countries, in Asia, Latin America and Africa. Systematic deployment of AS+MQ was shown effective to stop resistance and reduce malaria incidence along the border between northwestern Thailand and Myanmar.
|ASMQ in Latin America|
|In Latin America, ASMQ FDC was evaluated for programmatic use by the National Programme of Control of Malaria and Health Authorities of Brazil in the State of Acre (Amazon Basin) between 2006 and 2008. In this study, one year after the introduction of ASMQ FDC, P. falciparum malaria cases were reduced by 80% and malaria-related hospitalisations dropped by over 60%. The ratio of P. falciparum to P. vivax infections decreased from 70% to 20%; decreases in the proportion of patients with recurrent P. falciparum infections and in the proportion of slides with gametocytes were also observed.|
|ASMQ in Myanmar|
In 2009 in Myanmar, the effectiveness of all four WHO-recommended fixed-dose ACTs – artesunate-amodiaquine, dihydroartemisinin-piperaquine, artemether- lumefantrine and AS-MQ, including ASMQ FDC and loose AS+MQ – was compared in over 800 Burmese adults and children. ASMQ FDC had the highest cure rate and the lowest rate of gametocytes carriage, providing the greatest post-treatment suppression of recurrent P. falciparum malaria and the most effective suppression of blood-stage P. vivax malaria.
|ASMQ in Africa|
|In Africa, the use of AS+MQ has also been documented in 10 countries that provided data for over 1,800 patients treated with various dose regimens of AS+MQ loose combination since 1994 with overall very good efficacy results.|
Download more about ASMQ scientific evidence, [PDF 1.4MB]